PBAC Public Summary Documents – March 2020

Page last updated: 23 July 2020

Public Summary Documents relating to the March 2020 PBAC meeting.

• Acalabrutinib: Capsule 100 mg; Calquence®
• Adalimumab: Injection 40 mg in 0.8 ml pre-filled syringe, 2; Injection 40 mg in 0.8 ml pre-filled pen, 2; Injection 40 mg in 0.8 ml pre-filled syringe, 6; Injection 40 mg in 0.8 ml pre-filled pen, 6; Hyrimoz®
• Alirocumab: Injection 75 mg in 1 ml single dose pre-filled pen injection 150 mg in 1 ml single dose pre-filled pen; Praluent®
• Amino acid formula with vitamins and minerals without phenylalanine: Sachets containing oral powder 27.8 g, 30; PKU Lophlex®
• Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids: Oral powder 400 g; (Neocate® LCP); Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids: Oral powder 400g; Neocate® Syneo
• Apomorphine: Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 ml, Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 ml pre-filled pen; Apomine® Solution for infusion and Apomine® Intermittent
• Atezolizumab (TNBC): Solution concentrate for I.V. infusion 840 mg in 14 ml; Tecentriq®
• Atezolizumab (SCLC): Solution concentrate for I.V. infusion 840 mg in 14 ml; Tecentriq®
• Avelumab: Solution concentrate for I.V. infusion 200 mg in 10 ml; Bavencio®
• Benralizumab: Injection 30 mg in 1 ml pre-filled pen; Fasenra Pen®
• Bezlotoxumab: Solution concentrate for I.V. infusion 1000 mg in 40 ml; Zinplava®
• Brolucizumab: Solution for intravitreal injection 19.8 mg in 0.165 ml pre-filled syringe; Beovu®
• Buprenorphine with Naloxone: Tablet (sublingual) containing 0.7 mg buprenorphine hydrochloride with 0.18 mg naloxone hydrochloride, Tablet (sublingual) containing 1.4 mg buprenorphine hydrochloride and 0.36 mg naloxone hydrochloride, Tablet (sublingual) containing 2.9 mg buprenorphine hydrochloride and 0.71mg naloxone hydrochloride, Tablet (sublingual) containing 5.7 mg buprenorphine hydrochloride and 1.4 mg naloxone hydrochloride, Tablet (sublingual) containing 8.6 mg and 2.1mg naloxone hydrochloride, Tablet (sublingual) containing 11.4 mg buprenorphine hydrochloride and 2.9 mg naloxone hydrochloride; Zubsolv®
• Cabozantinib: Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
• Dupilumab: Injection 300 mg in 2 ml single use pre-filled syringe; Dupixent®
• Entrectinib: Capsule 200 mg; Rozlytrek®
• Fluocinolone acetonide: Intravitreal injection 190 micrograms; Iluvien®
• Fremanezumab: Injection 225 mg in 1.5 mL pre-filled syringe; Ajovy®
• Lisdexamfetamine: Capsule containing lisdexamfetamine dimesilate 20mg, 30mg, 40mg, 50mg, 60mg, 70mg; Vyvanse®
• Mepolizumab: Injection 100 mg in 1 ml pre-filled pen, Injection 100 mg in 1 ml pre-filled syringe; Nucala®
• Mesalazine: Suppository 1g sachet containing granules, 1 g per sachet; Pentasa®
• Methylphenidate: Capsule containing methylphenidate hydrochloride 60 mg (modified release); Ritalin LA®
• Milk protein and fat formula with vitamins and minerals - carbohydrate free: Oral powder 225 g, Carbohydrate Free Mixture®
• Nabiximols: Oromucosal spray, 8 mg per dose, 90 doses; Sativex®
• Olaparib: Capsule 50 mg, Tablet 100 mg, Tablet 150 mg; Lynparza®
• Ondansetron: Wafer 4 mg, 8 mg; Tablet (as hydrochloride dehydrate) 4 mg, 8 mg; Tablet (orally disintegrating) 4 mg, 8 mg; various brands
• Ozanimod: Capsule 230 micrograms, 460 micrograms and 920 micrograms; Zeposia®
• Pegfilgrastim: Injection 6 mg in 0.6 ml single use pre-filled syringe; Pelgraz®
• Pembrolizumab (melanoma, NSCLC): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda®
• Pembrolizumab (melanoma): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda®
• Pembrolizumab (melanoma resubmission): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda®
• Pembrolizumab (PMBCL): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda®
• Pertuzumab: Solution for I.V. infusion 420 mg in 14 ml; Perjeta®
• Plitidepsin: Powder for I.V infusion 2 mg with 4 ml solvent; Aplidin®
• Protein formula with carbohydrate, fat, vitamins, minerals and transforming growth factor beta-2: Powder for oral liquid, 400 g, 12; Modulen® IBD
• Rivaroxaban: Tablet 2.5 mg; Xarelto®
• Romosozumab: Injection 105 mg in 1.17 ml single use pre-filled syringe; Evenity®
• Salbutamol: Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation), Ventolin®
• Semaglutide: Injection 2 mg in 1.5 ml pre-filled syringe; Injection 4 mg in 3 ml pre-filled syringe; Ozempic®
• Stiripentol: Capsule 250 mg, Capsule 500mg, Powder for oral suspension 250 mg, Powder for oral suspension 500 mg; Diacomit®
• Tocilizumab: Injection 162 mg in 0.9 ml single use pre-filled pen, Injection 162 mg in 0.9 ml single use pre-filled syringe; Actemra®
• Tofacitinib: Tablet 5 mg; Xeljanz®
• Triglycerides medium chain formula: Oral powder 400 g; Peptamen® Junior
• Triglycerides medium chain and long chain with glucose polymer: Oral powder 400 g; Duocal®
• Triglycerides medium chain formula: Oral powder 400 g; Lipistart®
• Venetoclax: Tablet 10 mg, Tablet 50 mg, Tablet 100 mg; Venclexta®
• Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, low in protein, phosphate, potassium and lactose oral powder 400 g, 6 sachets containing oral powder 100 g, 10; Renastart®